Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Boehringer Ingelheim
McKesson
Colorcon
Johnson and Johnson

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Bexagliflozin


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Bexagliflozin?

Bexagliflozin is an investigational drug.

There have been 16 clinical trials for Bexagliflozin. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2015.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Hypertension. The leading clinical trial sponsors are Theracos and [disabled in preview].

There are eighteen US patents protecting this investigational drug and two hundred and six international patents.

Recent Clinical Trials for Bexagliflozin
TitleSponsorPhase
Absolute Bioavailability Study With BexagliflozinTheracosPhase 1
Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic ImpairmentTheracosPhase 1
Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes SubjectsTheracosPhase 3

See all Bexagliflozin clinical trials

Clinical Trial Summary for Bexagliflozin

Top disease conditions for Bexagliflozin
Top clinical trial sponsors for Bexagliflozin

See all Bexagliflozin clinical trials

US Patents for Bexagliflozin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Bexagliflozin ⤷  Try it Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Try it Free
Bexagliflozin ⤷  Try it Free GPR40 agonists in anti-diabetic drug combinations Janssen Pharmaceutica NV (Beerse, BE) ⤷  Try it Free
Bexagliflozin ⤷  Try it Free Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) ⤷  Try it Free
Bexagliflozin ⤷  Try it Free Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) ⤷  Try it Free
Bexagliflozin ⤷  Try it Free Compounds as peptidic GLP1/glucagon/GIP receptor agonists SANOFI (Paris, FR) ⤷  Try it Free
Bexagliflozin ⤷  Try it Free Crystalline form of benzylbenzene SGLT2 inhibitor THERACOS SUB, LLC (Marlborough, MA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Bexagliflozin

Drugname Country Document Number Estimated Expiration Related US Patent
Bexagliflozin Australia AU2017261372 2036-05-05 ⤷  Try it Free
Bexagliflozin Canada CA3023278 2036-05-05 ⤷  Try it Free
Bexagliflozin China CN107847398 2036-05-05 ⤷  Try it Free
Bexagliflozin European Patent Office EP3452003 2036-05-05 ⤷  Try it Free
Bexagliflozin Hong Kong HK1249728 2036-05-05 ⤷  Try it Free
Bexagliflozin Japan JP2019520866 2036-05-05 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Boehringer Ingelheim
McKesson
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.